Regulator Cracks Down on GLP-1 Weight Loss Drug Supply Chain
Advisory Issued, 49 Entities Inspected Amid Rising Misuse Concerns
New Delhi: India’s drug regulator has stepped up surveillance over the supply chain of GLP-1-based weight loss drugs, intensifying enforcement against unauthorized sale, misleading promotion, and unsafe usage practices.
The move comes amid growing concerns over the increasing availability of generic variants of these drugs across retail pharmacies, online platforms, wholesalers, and wellness clinics. Officials have flagged the risk of unsupervised consumption, which could lead to serious health complications.
The Drugs Controller of India, in coordination with state regulators, has launched targeted action to curb malpractices and ensure compliance across the pharmaceutical ecosystem.
On March 10, the regulator issued a comprehensive advisory to manufacturers, prohibiting surrogate advertisements and any indirect promotion that may mislead consumers or encourage off-label use.
Enforcement efforts have gathered pace in recent weeks, with inspections carried out at 49 entities, including online pharmacy warehouses, drug wholesalers, retailers, and slimming clinics. These inspections, conducted across multiple regions, focused on violations related to unauthorized sale, improper prescription practices, and misleading marketing claims. Notices have been issued to entities found in violation.
The regulator reiterated that patient safety remains paramount, warning that the use of weight loss drugs without proper medical supervision can result in severe adverse effects.
GLP-1-based drugs are approved in India strictly for prescription use by endocrinologists and internal medicine specialists, and in certain cases by cardiologists. Authorities have cautioned that any deviation from these norms will invite stringent action, including license cancellation, financial penalties, and prosecution under applicable laws.
Regulatory surveillance is expected to intensify further in the coming weeks as authorities seek to tighten oversight of this fast-expanding drug segment.
